In8bio Reports Updated Glioblastoma Data At SNO 2026 Demonstrating Median Overall Survival Of 20.9 Months And 50% Two-Year Survival With Gamma-Delta T Cell Therapy
| Treatment Arm | Median PFS (months) | Median OS (months) | Patients Alive at Two Years (%) |
| Historical NEJM Data | 6.9 | 14.6 | 26.5% |
| Control (SOC) Patients | 6.6 | 13.2 | (1/10) 10% |
| INB-200 DL1 Patients | 8.0 | 15.7 | (0/3) 0% |
| INB-200 Repeat Dose Patients | 16.1 | 21.1 | (5/10)* 50% |
| INB-400 Repeat Dose Patients | 13.0 | 20.9 | (2/4) 50% |
| All Repeat Dose Patients | 13.0 | 20.9 | (7/14) 50% |
Note: As of October 30, 2026. *Patients 007 and 014 passed away from cardiovascular events without progression. Patients without progression who are no longer alive are not censored in this analysis. Early trial results are not indicative of future results, including the outcome of this trial.
Total surgical resection was performed in 43% of repeat-dose patients, compared with 80% of SOC control patients.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also developing INB-100, an allogeneic γδ T cell therapy candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell therapy candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit .
Investors and Corporate Contact:
IN8bio, Inc.
Patrick McCall
646.933.5603
...
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
...

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment